Combined inhibition of PI3K and mTOR exerts synergistic antiproliferative effect, but diminishes differentiative properties of rapamycin in acute myeloid leukemia cells. (Q53266494)

From Wikidata

Jump to navigation Jump to search

scientific article published on 19 February 2011

Language	Label	Description	Also known as
English	Combined inhibition of PI3K and mTOR exerts synergistic antiproliferative effect, but diminishes differentiative properties of rapamycin in acute myeloid leukemia cells.	scientific article published on 19 February 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21336564%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Combined inhibition of PI3K and mTOR exerts synergistic antiproliferative effect, but diminishes differentiative properties of rapamycin in acute myeloid leukemia cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21336564%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21336564%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

author name string

Josko Mise

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21336564%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Hrvoje Banfic

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21336564%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Dora Visnjic

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21336564%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

publication date

19 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21336564%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Pathology and Oncology Research

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21336564%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21336564%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21336564%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

645-656

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21336564%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Survival of acute myeloid leukemia cells requires PI3 kinase activation

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9365-Z

21 January 2018

Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9365-Z

21 January 2018

Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9365-Z

21 January 2018

Novel 2'-substituted, 3'-deoxy-phosphatidyl-myo-inositol analogues reduce drug resistance in human leukaemia cell lines with an activated phosphoinositide 3-kinase/Akt pathway

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9365-Z

21 January 2018

Exploiting the mammalian target of rapamycin pathway in hematologic malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9365-Z

21 January 2018

The two TORCs and Akt.

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9365-Z

21 January 2018

Antileukemic activity of rapamycin in acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9365-Z

21 January 2018

Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9365-Z

21 January 2018

A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9365-Z

21 January 2018

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9365-Z

21 January 2018

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9365-Z

21 January 2018

Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9365-Z

21 January 2018

Acute promyelocytic leukemia: from highly fatal to highly curable

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9365-Z

21 January 2018

Differentiation therapy of acute myeloid leukemia: past, present and future

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9365-Z

21 January 2018

The role of the nuclear Akt activation and Akt inhibitors in all-trans-retinoic acid-differentiated HL-60 cells

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9365-Z

21 January 2018

Inhibition of mammalian target of rapamycin signaling potentiates the effects of all-trans retinoic acid to induce growth arrest and differentiation of human acute myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9365-Z

21 January 2018

The activity of extracellular signal-regulated kinase is required during G2/M phase before metaphase-anaphase transition in synchronized leukemia cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9365-Z

21 January 2018

LY294002 and rapamycin co-operate to inhibit T-cell proliferation

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9365-Z

21 January 2018

Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9365-Z

21 January 2018

Additive effects of PI3-kinase and MAPK activities on NB4 cell granulocyte differentiation: potential role of phosphatidylinositol 3-kinase gamma

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9365-Z

21 January 2018

Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9365-Z

21 January 2018

The PI3K inhibitor arsenal: choose your weapon!

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9365-Z

21 January 2018

Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9365-Z

21 January 2018

PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML.

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9365-Z

21 January 2018

Activation of the p70 S6 kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9365-Z

21 January 2018

The Akt-mTOR tango and its relevance to cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9365-Z

21 January 2018

Phosphatidylinositol 3-kinase regulates PMA-induced differentiation and superoxide production in HL-60 cells

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9365-Z

21 January 2018

The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9365-Z

21 January 2018

Phosphoinositide 3-kinase activity is essential for all-trans-retinoic acid-induced granulocytic differentiation of HL-60 cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/21336564

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/21336564

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21336564

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model

1 reference

https://pubmed.ncbi.nlm.nih.gov/21336564

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Retinoic acid induced mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase-dependent MAP kinase activation needed to elicit HL-60 cell differentiation and growth arrest.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21336564

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MAPK-dependent expression of p21(WAF) and p27(kip1) in PMA-induced differentiation of HL60 cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/21336564

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12253-011-9365-Z

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21336564%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21336564%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53266494&oldid=2212054244"